Wide Ranks

GOSS

Gossamer Bio, Inc.

0.7017

Top Statistics
Market Cap 159 M Forward PE -1.01 Revenue Growth 0.00 %
Current Ratio 6.74 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -68.03 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -0.5760 Enterprise / Revenue 0.3380 Price To Sales Trailing12 Months 1.51
Profitability
Profit Margins -68.03 % Operating Margins -357.80 %
Balance Sheet
Total Cash 327 M Total Cash Per Share 1.44 Total Debt 203 M
Total Debt To Equity 376.14 Current Ratio 6.74 Book Value Per Share 0.2390
All Measures
Short Ratio 799.00 % Message Board Id finmb_548541911 Shares Short Prior Month 6 M
Return On Equity -0.9026 City San Diego Uuid b23a77d9-f4eb-3e8f-858d-367c07bb4901
Previous Close 0.7000 First Trade Date Epoch Utc 1 B Book Value 0.2390
Beta 1.96 Total Debt 203 M Volume 667311
Price To Book 2.94 Fifty Two Week Low 0.4990 Total Cash Per Share 1.44
Total Revenue 105 M Shares Short Previous Month Date 1 B Target Median Price 7.00
Max Age 86400 Sand P52 Week Change 0.3133 Operating Margins -357.80 %
Target Mean Price 6.72 Net Income To Common -71647000 Short Percent Of Float 0.0297
Implied Shares Outstanding 226 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 1 M Average Volume10days 1 M Total Cash 327 M
Next Fiscal Year End 1 B Revenue Per Share 0.4660 Held Percent Insiders 0.0333
Ebitda Margins -58.68 % Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 0.7000 Target Low Price 0.5000
Gmt Off Set Milliseconds -18000000 Fifty Day Average 0.8992 Open 0.7000
Free Cashflow -2626500 State CA Dividend Yield 0.00 %
Return On Assets -0.1124 Time Zone Short Name EST Trailing Eps -0.2500
Day Low 0.6901 Address1 3013 Science Park Road Shares Outstanding 226 M
Price Hint 4 Target High Price 15.00 Website https://www.gossamerbio.com
52 Week Change -0.1023 Average Volume 923926 Forward Eps -0.6900
Recommendation Key none Compensation As Of Epoch Date 1 B Quick Ratio 653.10 %
Is_sp_500 False Regular Market Day High 0.7200 Profit Margins -68.03 %
Debt To Equity 376.14 Fifty Two Week High 1.60 Day High 0.7200
Shares Short 6 M Regular Market Open 0.7000 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue 0.3380 Revenue Growth 0.00 %
Shares Percent Shares Out 0.0288 Operating Cashflow -1411000 Currency USD
Time Zone Full Name America/New_York Market Cap 159 M Is_nasdaq_100 False
Zip 92121 Quote Type EQUITY Industry Biotechnology
Long Name Gossamer Bio, Inc. Regular Market Day Low 0.6901 Held Percent Institutions 0.7746
Current Price 0.7017 Address2 Suite 200 Enterprise To Ebitda -0.5760
Financial Currency USD Current Ratio 6.74 Gross Margins 100.00 %
Industry Disp Biotechnology Number Of Analyst Opinions 8 Country United States
Float Shares 187 M Two Hundred Day Average 0.9317 Enterprise Value 35 M
Price To Sales Trailing12 Months 1.51 Forward PE -1.01 Regular Market Volume 667311
Ebitda -61801000 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States.

The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.

It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds.

The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017.

Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.